Title
Remote Application and Use of Real-Time Continuous Glucose Monitoring by Adults with Type 2 Diabetes in a Virtual Diabetes Clinic.

Permalink
https://escholarship.org/uc/item/2297v2nh

Journal
Diabetes technology & therapeutics, 23(2)

ISSN
1520-9156

Authors
Bergenstal, Richard M
Layne, Jennifer E
Zisser, Howard
et al.

Publication Date
2021-02-01

DOI
10.1089/dia.2020.0396

Peer reviewed
Remote Application and Use of Real-Time Continuous Glucose Monitoring by Adults with Type 2 Diabetes in a Virtual Diabetes Clinic

Richard M. Bergenstal, MD,1 Jennifer E. Layne, PhD,2 Howard Zisser, MD,3 Robert A. Gabbay, MD, PhD,4 Nathan A. Barleen, BS,2 Amy Armento Lee, MS,3 Amit R. Majithia, MD,5 Christopher G. Parkin, MS,6 and Ronald F. Dixon, MD2

Abstract

The Onduo Virtual Diabetes Clinic (VDC) for people with type 2 diabetes (T2D) combines a mobile app, remote lifestyle coaching, connected devices, and live video consultations with board-certified endocrinologists. Adults with T2D (n = 594) who were evaluated by a VDC endocrinologist, remotely prescribed and mailed a real-time continuous glucose monitoring (rtCGM) device and used ≥1 sensor completed a CGM satisfaction questionnaire. The CGM satisfaction score was 4.5 ± 0.8 out of 5. Most respondents (94.7%) agreed/strongly agreed that they were comfortable inserting the sensor remotely and that rtCGM use improved understanding of the impact of eating (97.0%), increased diabetes knowledge (95.7%), and helped improve diabetes control when not wearing the sensor (79.4%). HbA1c (n = 372) decreased from 7.7% ± 1.6% to 7.1% ± 1.2% (P < 0.001; 10.2 months). These data suggest that it is feasible to provide rtCGM directly to individuals with T2D through a VDC without in-office training. Intermittent use of rtCGM was well-received by adults with T2D and was associated with improvement in HbA1c.

Keywords: HbA1c, CGM, Digital health, Telemedicine, Telehealth, Type 2 diabetes.

Introduction

Recent clinical trials have demonstrated the benefits of real-time continuous glucose monitoring (rtCGM) for people with insulin-treated type 2 diabetes (T2D).1–3 Despite these benefits, adoption of rtCGM in the T2D population has been limited by insurance coverage, the lack of awareness of rtCGM in the primary care setting, where the vast majority of people with T2D are treated, and limited access to diabetes care and education specialists.4 New approaches are needed to increase use of rtCGM and advanced technologies for people with T2D.

The Onduo Virtual Diabetes Clinic (VDC) is a comprehensive telehealth program for people with T2D with an innovative model for remotely prescribing and delivering rtCGM for intermittent use without the need for in-office training. The VDC program is designed to support people with T2D and their health care providers between offices. A detailed description of the program has been previously reported.5,6 In brief, the VDC program combines a mobile

1International Diabetes Center at Park Nicollet, HealthPartners Institute, Minneapolis, Minnesota, USA.
2Onduo, Newton, Massachusetts, USA.
3Verily Life Sciences, South San Francisco, California, USA.
4Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA.
5University of California San Diego, School of Medicine, La Jolla, California, USA.
6CGParkin Communications, Inc., Clinical Affairs, Henderson, Nevada, USA.

Some of these data were presented at the 13th International Conference on Advanced Technologies & Treatments for Diabetes, February 19–22, 2020 in Madrid, Spain.

© Richard M. Bergenstal, et al., 2020; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
App, remote personalized lifestyle coaching from certified diabetes care and education specialists and health coaches, and connected blood glucose meters and rtCGM devices. The VDC care model includes the availability of live video consultations with board-certified endocrinologists for medication management in addition to prescribing CGM. Participants interact with their care team primarily through the VDC App, which tracks data relevant to participants’ diabetes care. Participants are eligible for CGM if they met any of the following criteria at any time during their participation in the program: HbA1c >8.0%, use of insulin or a sulfonylurea, emergency department or urgent care visit in previous six months, no primary care physician (PCP) visit within the prior year, or at the discretion of the VDC endocrinologist. Glucose data are reviewed by the care team and used as a coaching tool in an educational feedback loop that allows participants to associate their glucose levels with their diet, lifestyle, and medication use to optimize self-management.

The objective of this observational survey study was to evaluate VDC program participants’ attitudes toward remotely prescribed rtCGM and the relationship between rtCGM use and change in HbA1c.

**Materials and Methods**

VDC participants with T2D were included in the analysis if they were clinically evaluated by a VDC endocrinologist, prescribed a rtCGM device, and used ≥1 sensor from March 2018 through July 2019. Depending upon U.S. Food and Drug Administration (FDA) availability, participants were initially mailed either four Dexcom G5 (7-day wear) sensors or three Dexcom G6 (10-day wear) sensors (Dexcom, San Diego, CA), which were provided in one shipment, respectively. The VDC care team provided training videos to help members insert the sensor and onboard to using the rtCGM device. The care team provided education to participants on rtCGM use and encouraged logging of meals, exercise, and medications in the VDC App while using rtCGM. Participants were encouraged but not required to perform the home HbA1c test. Intermittent sensor wear schedules were individualized based upon interactions with the care team and participant preferences. Participants were sent a CGM satisfaction questionnaire electronically via the VDC App. This analysis was approved by the Western Institutional Review Board.

**Outcomes**

CGM awareness and satisfaction. Participants were asked if they were familiar with CGM or had heard of CGM before joining the VDC program with yes or no response options. Participant satisfaction with rtCGM use was assessed using a subset of nine questions from the validated 44-item CGM Satisfaction Scale. Questions were selected to assess three CGM-related themes: educational value, impact on diabetes self-management, and device satisfaction. Response to each item was assessed on a 5-point Likert scale: 1 = strongly disagree, 5 = strongly agree.

Change in HbA1c. Change in HbA1c was evaluated as the difference between the most recent HbA1c level obtained before using the first sensor (baseline) and the most recent HbA1c ≥90 days after the baseline sensor wear (follow-up). HbA1c data were obtained from a central laboratory analyzing the participant home-test samples or verified with the primary care physician by the health coach or obtained directly from the provider or medical record. HbA1c testing is requested, but not required for program participation, thus data were only available for a subset of participants.

**Statistical analysis**

Baseline characteristics of survey respondents and nonrespondents were summarized and compared. All subsequent analyses were performed only for survey respondents. Overall mean satisfaction score was calculated based upon the sum of responses to the nine satisfaction-related questions with reverse scoring applied to the negatively worded question (“CGM sometimes gives me too much information to work with.”). Mean score for each question was also summarized. All glycemic outcomes were evaluated by two-tailed t-tests using R software. Statistical significance was defined as P < 0.05.

**Results**

A total of 761 participants were sent the satisfaction survey and 594 (78.1%) responded. Baseline demographic and clinical characteristics of survey respondents and nonrespondents are presented in Table 1.

**Sensor use**

Of the survey respondents, 279 (47.0%) participants received the G5 sensor, 290 (48.8%) received G6, and 25 (4.2%) received both types of sensors. Mean days of sensor wear was 31.1 ± 26.5 days intermittently over a period of 4.8 ± 3.2 months. The intermittent sensor wear schedule was individualized, and timing varied based upon care team recommendations and participant preferences.

**Table 1. Participant Characteristics**

| Variable                      | Survey respondents (n = 594) | Nonrespondents (n = 168) | P     |
|-------------------------------|-----------------------------|--------------------------|-------|
| Age, year                     | 53.0 ± 8.4                  | 48.5 ± 9.4               | <0.001|
| Female, n (%)                 | 370 (62.3)                  | 107 (64.1)               | 0.74  |
| Body mass index (kg/m²)       | 35.4 ± 7.7                  | 36.1 ± 7.4               | 0.28  |
| Baseline HbA1c (%)            | 7.7 ± 1.6                   | 8.0 ± 1.7                | 0.035 |
| Medication use, n (%)         |                            |                          |       |
| Sulfonylurea                  | 153 (25.8)                  | 35 (21.0)                | 0.24  |
| Insulin                       | 217 (36.5)                  | 63 (37.7)                | 0.84  |
| Geography, n (%)              |                            |                          | 0.99  |
| Urban                         | 425 (72.5)                  | 119 (72.1)               |       |
| Rural                         | 161 (27.5)                  | 46 (27.9)                |       |

Data are presented as mean ± standard deviation unless otherwise indicated.

aOut of a total n=550.
bOut of a total n=147.
cOut of a total n=563.
dOut of a total n=148.
eOut of a total n=586.
fOut of a total n=165.
rtCGM awareness and satisfaction

Among the 594 survey respondents, 60.8% indicated that they were not familiar with or had not heard of CGM before participation in the VDC program.

The mean overall rtCGM satisfaction score was 4.5 out of 5. The majority of respondents indicated agreement or strong agreement that rtCGM use increased their diabetes knowledge; improved their understanding of medication importance; made it easier to perform other self-management behaviors; improved their understanding of how food impacts their diabetes control; increased their understanding of how everyday tasks impact their diabetes; and helped improve their diabetes control when not wearing the rtCGM device. A majority of respondents agreed or strongly agreed that they felt comfortable inserting the rtCGM sensor (94.7%) and 88.4% indicated that they would like to use rtCGM again. Most respondents, 70.5%, disagreed or strongly disagreed that CGM provided too much data.

No differences in overall satisfaction were observed for insulin users (n = 217) compared to noninsulin users (n = 377) (P = 0.77), participants meeting the American Diabetes Association (ADA) treatment of HbA1c < 7.0% (n = 209), or participants above target (n = 354) (P = 0.07). There were also no differences between Dexcom G5 (n = 279) and G6 (n = 290) users (P = 0.32).

Change in HbA1c

The mean follow-up time-period for HbA1c measurement (n = 372) was 10.2 ± 4.0 months. The mean time-period from the initial sensor wear to the follow-up HbA1c measurement was 8.3 ± 3.8 months. Significant reductions in HbA1c from baseline were observed within the total respondent cohort, from 7.7% ± 1.6% to 7.1% ± 1.2%, change −0.6% ± 1.5%, P < 0.001. There was no difference in the overall change in HbA1c between survey respondents and non-respondents (n = 54). Change in HbA1c stratified by baseline categories of >9.0%, 8.0% to 9.0%, and 7.0% to <8.0% is presented in Figure 1.

The percentage of participants achieving Health Effectiveness Data Information Set (HEDIS) HbA1c treatment target (HbA1c < 8.0%) increased from 46.0% at baseline to 65.3% at follow-up in the insulin user group and from 78.6% at baseline to 93.1% at follow-up in the noninsulin user group. Significant reductions in HbA1c were observed at follow-up in both the insulin and noninsulin user groups with a baseline HbA1c ≥8.0%, −1.5% ± 2.1% and −2.0% ± 1.7%, respectively (both P < 0.001). In addition, a significant reduction in HbA1c was observed in participants with <30 days sensor wear (median wear time) and ≥30 days of sensor wear, −1.3% ± 1.8% and −2.1% ± 1.9%, respectively (both P < 0.001), the group of participants with baseline HbA1c ≥8.0%.

Discussion

This study demonstrated that through the Onduo VDC, it is feasible to remotely prescribe and mail rtCGM devices to people with T2D and for participants to successfully insert sensors and use rtCGM without in-office training. This may extend use of CGM to the primary care setting where there is often limited diabetes educator support. Intermittent use of CGM was well-received by VDC participants who reported high satisfaction with rtCGM as an educational tool that positively influenced their perception of diabetes self-management. The use of rtCGM was associated with a significant improvement in HbA1c at 10 months in those not meeting the ADA treatment target, independent of insulin use. In addition, there was a large shift in the percentage of participants meeting the HEDIS HbA1c target of <8.0% at follow-up; this may have important clinical and economic implications. To our knowledge this is the first study to report findings of user acceptance and clinical outcomes associated with CGM use in a virtual diabetes management program.

Participants reported that rtCGM use increased their knowledge about the impact of food, medication use, and everyday activities on their glucose levels. It appears that rtCGM influenced participants’ health behaviors as evidenced by improvements in glycemic control. The finding that nearly 80% of participants reported that rtCGM helped them improve their diabetes control even when not wearing their device suggests a possible beneficial carryover effect. Moreover, nearly 90% of participants reported that they

![FIG. 1. Change in HbA1c stratified by baseline HbA1c.](image-url)
would like to use rtCGM in the future if made available. It was interesting to note that individuals who were already meeting the ADA treatment target for HbA1c reported similar overall satisfaction with rtCGM use compared with those with higher HbA1c levels.

While persistent daily use of rtCGM is considered essential for intensive insulin management, clinical trials and recent meta-analyses have reported the value of rtCGM use in individuals with T2D independent of their treatment regimen. The real-world data included in this report add to the growing body of evidence indicating that intermittent rtCGM use with less intensive treatment regimens is associated with significant glycemic improvements, and creates valuable teaching opportunities, and is effective in promoting desired self-care behaviors.

Our study has some limitations. First, although the items included in our survey were derived from a validated assessment instrument, we used a subset of these questions in our survey, which may not fully represent participant experience with other aspects of rtCGM use. Second, there may have been response bias in this study: those who responded to the survey were older and had lower baseline HbA1c levels. In addition, respondents and non-respondents who elected to provide follow-up HbA1c (which was not required) may have differed from those who did not provide follow-up data. Third, in this real-world observational study, there was no control group. Engagement and program interaction and the impact on outcomes were not evaluated in this analysis but is currently being evaluated in an ongoing investigation. In addition, further investigation is needed to determine the cadence of intermittent rtCGM use and stepped coaching in the VDC care model. Analyses of other rtCGM metrics (e.g., time in range, time above range, and glucose management indicator) are underway in ongoing studies and these results should further elucidate the impact and potential benefits of rtCGM use in adults with T2D.

Conclusion

Remote prescription of rtCGM for intermittent use as part of the overall VDC care model was well-received by participants with T2D, the majority of whom indicated that they were comfortable inserting their sensors at home. Overall, the results of this study suggest that intermittent use of rtCGM was a beneficial diabetes management tool that increased participants’ knowledge about the impact and importance of diabetes care behaviors, enhanced engagement in their self-management regimens, and was associated with improvements in glycemic control. Access to rtCGM and specialist care through the VDC program is a novel approach to support people with T2D managed in primary care.

Authors’ Contributions

R.M.B., J.E.L., H.Z., R.A.G., N.A.B., and R.F.D., contributed to the concept and design of the study. N.A.B., R.M.B., J.E.L., R.F.D., and C.G.P. contributed to the acquisition, analysis, and interpretation of the data. N.A.B and A.A.L. contributed to statistical analyses. J.E.L. and C.G.P. wrote the first draft of the article. All authors contributed to critical revision of the article for important intellectual content. R.M.B. had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Acknowledgments

We thank the Onduo care leads, certified diabetes care and education specialists and physicians for their dedication to participant care.

Author Disclosure Statement

R.M.B. has received research support, consulted, or has been on the scientific advisory board for Abbott Diabetes Care, Dexcom, Hygieia, Johnson & Johnson, Lilly, Medtronic, Novo Nordisk, Onduo LLC, Roche, Sanofi, and United Healthcare. R.M.B.’s employer, nonprofit HealthPartners Institute, contracts for his services and no personal income goes to R.M.B. R.A.G. has received consulting fees from Form Health, Health Reveal, Lark Health, Onduo LLC and Vida Health. A.R.M. has received consulting fees from Onduo LLC. C.G.P. has received consulting fees from Abbott Diabetes Care, American Diabetes Association, American Association of Clinical Endocrinologists, Dexcom, Diasome, Onduo LLC, Novo Nordisk and Roche Diabetes Care. J.E.L, R.F.D., and N.A.B. are employees of Onduo LLC. Onduo is a joint venture of Verily and Sanofi. H.Z. and A.A.L. are employees of Verily Life Sciences.

Funding Information

This project was supported by Onduo LLC, Newton, MA. The Onduo authors herein are researchers, clinicians, and biostatisticians and worked in collaboration with the coauthors in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, and approval of the article; and decision to submit the article for publication.

References

1. Beck RW, Riddlesworth TD, Ruedy K, et al.: Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med 2017;167:365–374.
2. Haak T, Hanaire H, Ajjan R, et al.: Use of flash glucose sensing technology for 12 months as a replacement for blood glucose monitoring in insulin-treated type 2 diabetes. Diabetes Ther 2017;8:573–586.
3. Haak T, Hanaire H, Ajjan R, et al.: Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther 2017;8:55–73.
4. Rodbard D: Continuous glucose monitoring: a review of successes, challenges, and opportunities. Diabetes Technol Ther 2016;18(Suppl. 2):S2-3–S2-13.
5. Dixon RF, Zisser H, Layne JE, et al.: A smartphone-based type 2 diabetes clinic using video endocrinology consultations and CGM. J Diabetes Sci Technol 2019. DOI: 10.1177/1932296819888862.
6. Polonsky WH, Layne JE, Parkin CG, et al.: Impact of participation in a virtual diabetes clinic on diabetes-related distress in individuals with type 2 diabetes. Clin Diabetes 2020;cd190105. DOI: 10.2337/cd19-0105.
7. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group: Validation of measures of satisfaction with and impact of continuous and conventional glucose monitoring. Diabetes Technol Ther 2010;12: 679–684.

8. RDevelopment Core Team: R: a language and environment for statistical computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing, 2008. www.R-project.org (Accessed April 14, 2019).

9. Beck RW, Riddlesworth T, Ruedy K, et al.: Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA 2017;317: 371–378.

10. Aleppo G, Ruedy KJ, Riddlesworth TD, et al.: REPLACE-BG: a randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes. Diabetes Care 2017;40: 538–545.

11. Lind M, Polonsky W, Hirsch IB: Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA 2017;317: 379–387.

12. Šoupal J, Petruželková L, Grunberger G, et al.: Glycemic outcomes in adults with T1D are impacted more by continuous glucose monitoring than by insulin delivery method: 3 years of follow-up from the COMISAIR study. Diabetes Care 2020;43: 37–43.

13. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, et al.: Novel glucose-sensing technology and hypoglycemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet 2016;388: 2254–2263.

14. Oskarsson P, Antuna R, Geelhoed-Duijvestijn P, et al.: Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial. Diabetologia 2018; 61: 539–550.

15. Ida S, Kaneko R, Murata K: Utility of real-time and retrospective continuous glucose monitoring in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. J Diabetes Res 2019;2019: 4684815.

16. Taylor PJ, Thompson CH, Brinkworth GD: Effectiveness and acceptability of continuous glucose monitoring for type 2 diabetes management: a narrative review. J Diabetes Invest 2018;9: 713–725.

17. Park C, Le QA: The effectiveness of continuous glucose monitoring in patients with type 2 diabetes: a systematic review of literature and meta-analysis. Diabetes Technol Ther 2018;20: 613–621.

18. Janapala RN, Jayaraj JS, Fathima N, et al.: Continuous glucose monitoring versus self-monitoring of blood glucose in type 2 diabetes mellitus: a systematic review with meta-analysis. Cureus 2019;11:e5634.

19. Vigersky RA, Fonda SJ, Chellappa M, et al.: Short- and long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes. Diabetes Care 2012; 35: 32–38.

20. Yoo HJ, An HG, Park SY, et al.: Use of a real time continuous glucose monitoring system as a motivational device for poorly controlled type 2 diabetes. Diabetes Res Clin Pract 2008; 82: 73–79.

21. Ehrhardt NM, Chellappa M, Walker MS, et al.: The effect of real-time continuous glucose monitoring on glycemic control in patients with type 2 diabetes mellitus. J Diabetes Sci Technol 2011;5: 668–675.

22. Allen NA, Fain JA, Braun B, Chipkin SR: Continuous glucose monitoring in non-insulin-using individuals with type 2 diabetes: acceptability, feasibility, and teaching opportunities. Diabetes Technol Ther 2009;11: 151–158.

Address correspondence to:
Richard M. Bergenstal, MD
International Diabetes Center at Park Nicollet
HealthPartners Institute
3800 Park Nicollet Boulevard
Minneapolis, MN 55416-2527
USA

E-mail: richard.bergenstal@parknicollet.com